Article Detail - JE Part A
Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R14 - Effective Multiple Dates, 2025
Date Posted: December 18, 2025
This Billing and Coding Article has been revised under contract numbers: 01111 (CA), 01211 (AS, GU, HI, NMI), 01311 (NV), and 01911 (CA, HI & Territories).
Effective Date: Multiple Dates, 2025
Summary of Changes:
Under Article Text revised Table 1 row 11 to read "NavDx". Under subheading Additional Test-specific Indications, Limitations and Instructions revised 2nd sentence to add "cancer". Revised "NavDX" to read "NavDx". Formatting was corrected throughout the article. This revision is effective 12/18/2025.
Under Article Text revised Table 1 row 9 to add "NeXT Personal Dx Breast MRD Recurrence Monitoring Test: WGS Assay Design + Plasma Initial Test (Personalis, Inc)". Revised row 10 to add "NeXT Personal Single Plasma Test (Personalis, Inc)". Under subheading Additional Test-specific Indications, Limitations and Instructions revised 2nd sentence to add "NeXT Personal". This revision is due to a new covered test that has successfully completed a TA and is effective for 10/7/2025.
Under subheading Additional Test-specific Indications, Limitations and Instructions revised 2nd sentence to add "and anal squamous cell". Under ICD-10 Codes that Support Medical Necessity Group 3: Codes added Z85.048. This revision is due a new covered test that has successfully completed a TA and is effective for 1/8/2025.
Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCDs or access it via the CMS MCD.
